<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article18</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/SAVE" style="display:block; margin-bottom:10px;">SAVE Original</a></li>
<h2><strong>SAVE</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Captopril in Patients with Left Ventricular Dysfunction After Myocardial Infarction". The New England Journal of Medicine. 1992. 327(10):669-677. PubMed•Full text•PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
6.1 Inclusion Criteria<br/>
6.2 Exclusion Criteria<br/>
6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
8.1 Primary Outcomes<br/>
8.2 Secondary Outcomes<br/>
9 Criticisms<br/>
10 Funding<br/>
11 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In patients with left ventricular dysfunction but not overt heart failure following myocardial infarction (MI), does treatment with the ACE inhibitor captopril reduce morbidity and mortality?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In patients with left ventricular dysfunction after MI, long-term administration of captopril was associated with improved survival, reduced cardiovascular mortality, fewer major cardiovascular events, and attenuated ventricular remodeling.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
The study randomized 2231 patients to either captopril or placebo. Patients had an ejection fraction (EF) ≤40% and were within 3 to 16 days post-MI, without symptoms of ongoing ischemia or manifest heart failure. The results over the mean 42-month follow-up showed a 19% reduction in all-cause mortality and significant reductions in cardiovascular mortality and morbidity in the captopril group compared to placebo.<br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
Current guidelines recommend ACE inhibitors in patients with systolic dysfunction, both symptomatic and asymptomatic, following MI to improve survival.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, double-blind, placebo-controlled randomized clinical trial<br/>
- N=2,231<br/>
    - Captopril: 1,115<br/>
    - Placebo: 1,116<br/>
- Setting: 112 hospitals in the United States and Canada<br/>
- Enrollment: January 1987 - January 1990<br/>
- Follow-up: Average of 42 months<br/>
- Analysis: Intention-to-treat<br/>
- Primary outcome: All-cause mortality<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Inclusion Criteria<br/>
- Survived the first 3 days post-MI<br/>
- Left ventricular ejection fraction ≤40%<br/>
- Age ≥21 and &lt;80<br/>
<br/>
Exclusion Criteria<br/>
- Contraindication to ACE inhibitor use<br/>
- Need for an ACE inhibitor for other indications (heart failure, hypertension)<br/>
- Serum creatinine &gt;2.5 mg/dL<br/>
- Unstable post-MI course<br/>
- Inability to consent or comply with follow-up<br/>
<br/>
Baseline Characteristics<br/>
- No significant differences between groups at baseline.<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Captopril: Initial dose of 12.5 mg (or 6.25 mg in select cases) with a target of 25 mg three times daily by end of hospital phase, and up to 50 mg three times daily as tolerated.<br/>
- Placebo: Administered following the same schedule as captopril.<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcomes<br/>
- 19% reduction in all-cause mortality (captopril group 20% vs. placebo group 25%; P=0.019)<br/>
<br/>
Secondary Outcomes<br/>
- 21% reduction in cardiovascular mortality (P=0.014)<br/>
- 37% reduction in development of severe heart failure (P&lt;0.001)<br/>
- 22% reduction in congestive heart failure requiring hospitalization (P=0.019)<br/>
- 25% reduction in recurrent myocardial infarction (P=0.015)<br/>
- Less deterioration in ejection fraction (captopril group 13% vs. placebo group 16%; P=0.168)<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- The potential impact of newer treatments and strategies for MI developed after the study period is not assessed.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
The trial was supported by a grant from the Bristol-Myers Squibb Institute for Pharmaceutical Research, which had no role in data management or unblinded information access.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
- The original publication in The New England Journal of Medicine (NEJM.org)
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
